MEDICINE SHOPPE INTERNATIONAL

For franchise investors navigating the complex and critical healthcare sector, the fundamental question often revolves around identifying opportunities that combine an essential service with a proven, patient-centric model. Medicine Shoppe International franchise presents itself as a compelling option within the pharmacies and drug stores category, offering pharmacists and independent investors a pathway into community-focused pharmaceutical care. The brand's deep roots trace back to 1968 when St. Louis pharmacist Michael Busch first established The Medicine Shoppe pharmacy, driven by a mission to deliver personalized service and pharmacist-managed care directly to his community. Recognizing the scalable potential of this patient-first philosophy, Busch founded Medicine Shoppe International, Inc. (MSI) in 1970, also based in St. Louis, Missouri, specifically to extend franchise-ownership opportunities, leading to the opening of the first franchised Medicine Shoppe pharmacy in 1971. Today, the PeerSense database indicates 94 total units, all of which are franchised, reflecting a pure-play franchise model. However, broader industry reports from 2025/2026 suggest a more expansive presence, with nearly 500 locations operating across the United States, including 297 owned by franchisees, while a February 2026 report specifies approximately 365 stores across 43 U.S. states complemented by over 120 international locations. Historically, the brand has demonstrated significant scale, with over 600 locations nationwide reported as early as 1973 and 595 total stores in 2013. Medicine Shoppe International’s global footprint extends beyond the United States to include Canada, China, India, Indonesia, and Japan, further solidified by an expansion into the Middle East in 2007 with five Medicine Shoppe pharmacies in Dubai, United Arab Emirates, through a master franchise agreement with the Al Zahrawi Group, marking its seventh country of operation. This extensive and evolving operational history, coupled with its acquisition by Cardinal Health in 1995 and subsequent expansion through the acquisition of Medicap Pharmacies Inc. in 2003, positions Medicine Shoppe International as a historically significant and strategically backed entity within the pharmaceutical services market. The brand’s enduring focus on patient-centered community pharmacies, providing a critical local healthcare resource, makes it a pertinent consideration for investors seeking a stable, impactful role in the healthcare delivery ecosystem, distinguishing it from more transactional retail pharmacy models.

The industry landscape for pharmacies and drug stores, the core category for Medicine Shoppe International franchise, is characterized by its essential nature and sustained demand, underpinned by several robust secular tailwinds. While specific total addressable market size and growth rate figures for this exact category are not provided in the research, the healthcare sector as a whole represents a multi-trillion-dollar economy in the U.S., with pharmaceutical services forming a foundational component. Key consumer trends are unequivocally driving demand for community pharmacies: an aging global population necessitates increased medication management and chronic disease care, fostering a greater reliance on accessible local pharmacists. Furthermore, a growing health consciousness among consumers, coupled with a preference for personalized service over impersonal large-chain interactions, directly aligns with Medicine Shoppe International’s founding mission of pharmacist-managed, patient-centered care. The increasing complexity of prescription medications and the ongoing shift towards preventative health and wellness further amplify the role of community pharmacists as trusted healthcare advisors. These macro forces create a resilient environment for franchise investment in this industry, as pharmacy services are largely recession-resistant and benefit from recurring customer needs. The competitive dynamics within the pharmacy sector are a blend of highly consolidated large national chains and a fragmented network of independent and franchised community pharmacies. Medicine Shoppe International, with its focus on a premium franchise opportunity within the Alternative Care sub-sector, carves out a distinct niche by emphasizing high-touch patient relationships and a pharmacist-driven model, differentiating itself from the volume-driven strategies of larger competitors. The ongoing demand for localized healthcare access, particularly in underserved regions, coupled with the trust inherent in a long-standing community pharmacy brand, generates significant opportunity for the Medicine Shoppe International franchise network to expand its footprint and deepen its market penetration. The continuous evolution of healthcare policies, often favoring community-based care and preventative services, also provides a supportive regulatory environment for this type of franchise model.

For prospective investors considering a Medicine Shoppe International franchise investment, understanding the financial architecture is paramount, positioning it as a substantial and premium opportunity within the Alternative Care sub-sector. The initial franchise fee structure exhibits some nuance across recent Franchise Disclosure Documents (FDDs). While the 2025 and 2026 FDD data predominantly lists the initial franchise fee as $0, reflecting a potentially attractive entry point for some programs, one specific 2026 document also noted a $10,000 fee for new franchisees, suggesting variations based on specific programs or agreements. This fee structure is noteworthy, especially when compared to the broader franchise market, where initial fees can often range from $25,000 to $50,000 or more. The total investment required to open a Medicine Shoppe International franchise is substantial, ranging from $478,000 to $961,000, according to the 2025/2026 FDD data. This range exceeds the sub-sector averages of $294,531 to $623,123, firmly establishing Medicine Shoppe International as a premium investment. Other FDD data points reinforce this, with a 2024 FDD indicating a range of $513,050 to $894,876, and a 2026 FDD stating $513,050 to $895,653. The spread in investment is primarily driven by factors such as the scale of leasehold improvements, which can range from $55,000 to $175,000, and the opening inventory requirements, set between $95,000 and $170,000. A detailed breakdown of initial expenditures from the 2025 FDD further clarifies the capital deployment: Furniture, Fixtures & Equipment at $42,000 – $95,000; Pre-Opening Costs from $3,000 – $10,000; Signs & Installation at $15,000 – $35,000; Grand Opening and Marketing from $4,000 – $34,000; Accounts Receivable Financing at $60,000 – $100,000; Computer and Pharmacy Equipment at $26,000 – $40,000; Retail Solutions from $0 – $14,075; Telepharmacy from $0 – $35,865; and Accreditation Costs from $3,050 – $7,500. Additionally, franchisees must allocate $175,000 – $245,000 for Additional Funds to cover the first three months of operation. Beyond the initial investment, Medicine Shoppe International franchisees are subject to ongoing fees: a royalty rate of 5% of gross sales as per 2025 data, though other 2026 data indicates a 3.00% royalty fee. For licensing a co-branded or full-branded store, a flat monthly fee of $599 is mentioned for a five-year term in 2026 data. Franchisees also contribute to an advertising fund, typically 1% of gross sales, supporting collective marketing efforts. The substantial total investment and ongoing fee structure underscore the commitment required for this franchise opportunity, reflecting the comprehensive nature of establishing and operating a patient-centered community pharmacy backed by a global healthcare services and products company like Cardinal Health, Inc., which acquired MSI in 1995. Cardinal Health, Inc. is headquartered in Dublin, Ohio, and as of April 2023, Brad Cochran serves as the Executive Vice President of retail distribution at Cardinal Health and President of Medicine Shoppe International Inc. (MSI), providing strong corporate leadership.

The operating model for a Medicine Shoppe International franchise is intrinsically linked to its founding mission of delivering personalized service and pharmacist-managed care, making the franchisee's role highly engaged and community-focused. Daily operations for a franchisee revolve around direct patient interaction, prescription fulfillment, medication therapy management, and offering a range of health and wellness services tailored to the local community's needs. The emphasis on "pharmacist-managed care" strongly implies an owner-operator model, where the franchisee, ideally a pharmacist or a hands-on investor, is deeply involved in the day-to-day clinical and business aspects of the pharmacy. While specific staffing requirements are not detailed, a typical community pharmacy necessitates a team including pharmacists, pharmacy technicians, and administrative support staff to ensure efficient and compliant operations. The format options, though not explicitly delineated as drive-thru or kiosk, are inherently designed for a community retail presence, evidenced by the significant investment allocated to Leasehold Improvements, ranging from $55,000 to $175,000, and Signs & Installation, between $15,000 and $35,000, suggesting a dedicated physical storefront. Medicine Shoppe International, backed by Cardinal Health, provides a robust framework of ongoing corporate support designed to empower its franchisees. This support extends beyond initial setup to include strategic guidance from field consultants, access to technology platforms essential for modern pharmacy operations, and comprehensive marketing programs funded by the 1% advertising fee on gross sales. The supply chain leverage provided by Cardinal Health, a global healthcare services and products company, is a critical advantage, ensuring access to a wide array of pharmaceutical products and efficient distribution channels. While specific details on the initial training program's duration or location are not available, the complexity of operating a pharmacy franchise implies comprehensive instruction covering operational procedures, patient care protocols, and business management. The brand's territory strategy demonstrates a concentrated presence in the Northeast and Midwest of the U.S., with particular strength in Pennsylvania and New York, complemented by solid secondary markets in Missouri, Indiana, and New Jersey. Medicine Shoppe International currently operates in 36 states plus Washington D.C., with the largest regional concentration of 98 franchise locations situated in the South, according to 2024 FDD data. This strategic geographical focus indicates established brand recognition and market penetration in these areas, while also highlighting opportunities for expansion in lighter-covered Southeast and Western regions. The franchise agreement term length is noted as a five-year term for licensing a co-branded or full-branded store, providing a clear operational horizon for franchisees.

For potential investors in a Medicine Shoppe International franchise, the absence of Item 19 financial performance data in the current Franchise Disclosure Document necessitates a nuanced approach to assessing unit-level economics. While specific average revenue, median revenue, or profit margins are not disclosed directly by the franchisor, a comprehensive understanding can be constructed through industry benchmarks, the brand's market positioning, and its historical growth trajectory. The substantial total investment range of $478,000 to $961,000, positioned as a "premium franchise opportunity" exceeding the Alternative Care sub-sector averages, implies an expectation of significant revenue generation and robust unit-level profitability to justify such a capital outlay. The ongoing royalty rates, specified as 5% of gross sales (2025 data) or 3.00% (other 2026 data), along with a 1% advertising fund contribution, are structured to support both franchisor services and a healthy franchisee return, suggesting a business model designed for strong performance. The long history of Medicine Shoppe International, having evolved significantly since its founding in 1968 and its acquisition by Cardinal Health in 1995, indicates a sustainable business model that has adapted through various economic cycles. The strategic expansion, including the acquisition of Medicap Pharmacies Inc. in 2003 and global ventures into countries like Canada, China, India, Indonesia, Japan, and the UAE, where it established five pharmacies in Dubai in 2007, further attests to the perceived value and operational viability of the brand. Unit count trends, while showing some fluctuations over decades, provide a historical context for the brand's scale. An older report from 1973 mentioned over 600 locations nationwide, peaking at 595 total stores in 2013. Data from 2010 showed 473 franchised locations, which subsequently decreased to 292 by 2024. However, more recent reports from 2025/2026 indicate nearly 500 locations across the United States, with 297 owned by franchisees, and a February 2026 report stating nearly 365 U.S. stores plus over 120 international locations. These varying unit counts across different reporting periods suggest a dynamic operational strategy, potentially involving refranchising, market optimization, or strategic closures and openings, rather than a linear growth path. The consistent investment by Cardinal Health, a global healthcare services and products company, in maintaining and expanding the Medicine Shoppe International brand, including the leadership of Brad Cochran as Executive Vice President of retail distribution at Cardinal Health and President of Medicine Shoppe International Inc. as of April 2023, signals continued corporate confidence in the franchise's underlying business strength and potential for profitability at the unit level.

The growth trajectory of Medicine Shoppe International franchise, while not always linear, demonstrates a pattern of strategic evolution and adaptation within the dynamic healthcare landscape. Historically, the brand boasted a significant footprint, with over 600 locations nationwide reported in 1973, underscoring its early dominance in the community pharmacy space. This scale was largely maintained, with 595 total stores noted in 2013. However, the number of franchised locations in the U.S. saw a decline from 473 in 2010 to 292 by 2024, as indicated by Franchise Disclosure Document (FDD) data. Despite this, more recent reports from 2025/2026 suggest a renewed or re-evaluated presence, with nearly 500 locations across the United States, including 297 franchised units, and a February 2026 report citing nearly 365 stores across 43 states in the U.S., complemented by over 120 international locations. These figures, alongside the PeerSense database showing 94 total franchised units, reflect a complex, multi-faceted growth narrative that points to ongoing market adjustments and strategic recalibrations rather than a simple contraction. Recent corporate developments have significantly shaped the brand's trajectory: Medicine Shoppe International's acquisition by Cardinal Health in 1995 provided substantial backing from a global healthcare services and products company. This was followed by MSI's further expansion in 2003 through the acquisition of Medicap Pharmacies Inc., broadening its network and market reach. A notable global expansion occurred in 2007, when MSI entered the Middle East market with five Medicine Shoppe pharmacies in Dubai, United Arab Emirates, through a master franchise agreement with the Al Zahrawi Group, marking its seventh country of operation and demonstrating a commitment to international growth. The brand’s competitive moat is built upon several key advantages: its long-standing brand recognition, originating in 1968, fosters trust within communities; the robust backing of Cardinal Health provides unparalleled supply chain scale, operational expertise, and capital resources; and its unwavering focus on personalized service and pharmacist-managed care differentiates it from larger, more transactional chain pharmacies. Medicine Shoppe International adapts to current market conditions by emphasizing patient-centered care, a model that aligns with evolving healthcare consumer preferences. The inclusion of "Telepharmacy" as an initial expenditure line item ($0 – $35,865) in the 2025 FDD breakdown signifies the brand's strategic embrace of digital transformation and remote healthcare solutions, ensuring its relevance in an increasingly digital health landscape.

The ideal candidate for a Medicine Shoppe International franchise is an individual deeply committed to the brand's core mission of patient-centered community pharmacy. Given the brand's founding by a pharmacist, Michael Busch, and its emphasis on "pharmacist-managed care," a background as a licensed pharmacist is highly advantageous, enabling direct engagement in the clinical aspects of the business. However, the opportunity is also extended to independent investors, suggesting that strong business acumen, management experience, and a passion for local healthcare services are equally critical. These investors would typically need to demonstrate the capacity to hire and manage qualified pharmacy professionals while overseeing the operational and financial performance of the franchise. While specific multi-unit expectations or requirements are not explicitly stated, the presence of a well-established franchise system with a long history suggests potential for growth for high-performing franchisees. Available territories for Medicine Shoppe International franchise opportunities are strategically focused, with a strong presence observed in the Northeast and Midwest of the U.S., particularly in Pennsylvania and New York. Solid secondary markets exist in Missouri, Indiana, and New Jersey, indicating established demand and operational success in these regions. The brand operates in 36 states plus Washington D.C., and according to 2024 FDD data, the largest regional concentration of 98 franchise locations is found in the South. This geographical spread highlights both mature markets and significant opportunities for expansion, particularly in the Southeast and Western regions where coverage is currently lighter, allowing new franchisees to tap into underserved areas. While a specific timeline from signing to opening is not provided, the detailed breakdown of initial expenditures, including pre-opening costs and leasehold improvements, implies a structured development process. The franchise agreement term length for licensing a co-branded or full-branded store is specified as a five-year term, providing a clear operational commitment period for franchisees.

For investors seeking a meaningful and financially robust opportunity within the essential healthcare sector, the Medicine Shoppe International franchise warrants serious due diligence. This brand offers a compelling investment thesis, combining a long and reputable history dating back to 1968 with the strategic backing of Cardinal Health, a global healthcare services and products company since its acquisition in 1995. The focus on patient-centered community pharmacies and pharmacist-managed care positions it squarely within a growing market segment driven by an aging population and increasing demand for personalized healthcare services. Despite the non-disclosure of Item 19 financial performance data, the substantial initial investment range of $478,000 to $961,000, exceeding sub-sector averages, signals a premium franchise opportunity with an expectation of strong unit-level economics. The brand's strategic presence across 36 U.S. states plus Washington D.C., alongside an international footprint in multiple countries, demonstrates its established market penetration and ongoing growth potential, particularly in identified expansion regions. This is not merely a retail transaction; it is an investment in a vital community healthcare asset, supported by a comprehensive corporate infrastructure and a commitment to adapting to modern healthcare needs, including telepharmacy solutions. PeerSense provides exclusive due diligence data including SBA lending history, FPI score of 48 (Fair), location maps with Google ratings, FDD financial data, and side-by-side comparison tools, offering unparalleled insights for informed decision-making. Explore the complete Medicine Shoppe International franchise profile on PeerSense to access the full suite of independent franchise intelligence data.